|
|
Post by liane on Nov 1, 2016 4:52:40 GMT -5
lakers, Boy doesn't that sound familiar - just change the names. But I still have the hope that our far superior product will prevail.
|
|
|
|
Post by kbrion77 on Nov 1, 2016 6:58:28 GMT -5
Pfizer scraps Exubera Pfizer withdraws its inhaleable insulin product Exubera from world markets despite spending significant amounts on manufacturing and marketing the product 30th September 2008 Pfizer has decided to withdraw its inhaleable insulin product Exubera from world markets despite spending significant amounts on manufacturing and marketing the product. Pfizer's CEO Jeffrey Kindler announced the withdrawal of Exubera on 18 October 2007, and the company incurred a USD 2.8bn charge for doing so. According to a report in the Wall Street Journal, while Kindler's decision to axe Exubera has made him popular among analysts for cutting back on costs, it has also caused ructions within the company's co-marketing partner, Nektar Therapeutics, and could undermine a key aspect of Pfizer's recovery strategy. Pfizer did not inform Nektar that it was going to remove Exubera from the market until the 18 October announcement. Nektar, understandably, has been pretty venomous in its criticism of Pfizer. The way in which Pfizer revealed the decision will no doubt make other existing and future partners nervous about doing business with the world's largest pharmaceutical company. A Pfizer spokesman defended the company's track record of partnering, saying that it had a strong record and was committed to building more. Despite the assurances, the lack of sensitivity on the part of Pfizer may come back to haunt it, when vying for other partners to help it plug its failing pipeline. So far in 2007, Pfizer has spent USD 775m to manufacture and promote Exubera, according to an estimate by Credit Suisse analysts. The reason is that insulin, due to its fragile small-molecule structure, costs more to manufacture than regular medicines.Normal business practice sees pharmaceutical companies keep their slow-selling or underperforming products on the market, in order to recoup as much revenue as possible. The present case is unusual, as the removal of any drug from the market is normally reserved for cases involving significant safety concerns, or in response to regulators' demands. Neither of these situations occurred with Exubera. For example, Pfizer's blockbuster cholesterol fighter Lipitor (atorvastatin) costs USD 0.08 for every USD 1 it sells. Exubera, on the other hand, costs Pfizer about USD 0.30 for every USD 1, according to the analysts. The company informed investors that Exubera racked up only USD 12m in sales, which was far from a break-even result. The reason Exubera costs so much to produce is that it is manufactured in Germany, shipped to California to be sprayed and turned into a powder, packaged into blisters elsewhere and then inserted into a device in another US state. Also, promoting the drug to primary-care doctors requires a big budget spend.
Pfizer also pays licensor Nektar approximately 15 per cent of sales. It also paid the company to manufacture the delivery device and spray-dry the powder. As a result, in Q1 FY07 Pfizer paid Nektar approximately USD 60m.Pfizer has spent in the region of USD 370m so far in 2007 to promote Exubera. Activities have included the sending of special diabetes educators to doctors to teach them how to use the new device, as well as DTC advertising investment. In comparison, say Credit Swiss analysts, the promotion of Pfizer's new cancer drug Sutent (imatinib), only cost Pfizer USD 200m. Nektar may take over sales and marketing Nektar is now free to market Exubera alone, according to WR Hambrecht & Co analysts. They say that Pfizer has manufactured enough of the product to last several years, given current demand. Because Nektar is a smaller company, its marketing costs would be much lower, so it would not have to sell as much Exubera to make a profit. Nektar could launch Exubera as a discounted product and lower the price 30 per cent or more to make it more attractive. Nektar is developing treatments for cystic fibrosis, cancer and a treatment for constipation as a side effect of pain drugs. In 2007, German-headquartered Bayer paid Nektar USD 50m to share the rights to an inhaled antibiotic it was working on, plus up to USD 125m more should Nektar meet development milestones. 30th September 2008 www.pmlive.com/pharma_news/pfizer_scraps_exubera_9168?SQ_DESIGN_NAME=2&Honestly how many times can this be posted and please tell me exactly what relevance does it have to do with MNKD today? Outside of the "Insulin Put" Sanofi is completely out of the picture. Pfizer paid Nektar $135M a month after they terminated the partnership, it has been 10 months since termination and people are still expecting some type of payout?  It's posts like these that just drive me nuts on here if I posted an article about when Dendreon filed for Chapter 11 it would get crucified as FUD. |
|
|
|
Post by silentknight on Nov 1, 2016 8:25:19 GMT -5
There are some silimarities with Exubera, even if people don't want to acknowledge them, despite the fact that that Afrezza is superior in every way. Endos who have been around for a while probably remember the Exubera disaster and punish Afrezza unjustifiably because of it. Bad experiences are hard to overcome, especially with the slow-to-change medical field. That's why doctor education is so important, and in that respect, the label isn't helping much. MNKD needs to be able to point to certifiable evidence that Afrezza is fundamentally different and demonstrably more effective than Exubera ever was. Currently, without a label change, they can't say that, nor can they say it's more effective than other insulins. Patients can, but patients aren't visiting doctor's offices and holding dinners to try and sell Afrezza and their sporadic insistence on the drug hasn't been too effective thus far. I'm hoping MNKD sheds some light on the FDA submission for the planned label change at the CC next week. It needed to be in immediately after the papers were published at the conference a few months ago. Every day matters especially given MNKDs precarious situation.
In terms of SNY, I don't think we'll be seeing some settlement money coming down the pipe from them at all. If we're extremely lucky, MNKD might negotiate some debt forgiveness and see the lien on Valencia removed. Pair that with the insulin put that SNY is paying and that'll probably be all MNKD will ever see. I think they owe more for their failed and incredibly lacking efforts buts an independent arbitrator would probably rule against MNKD in a mediation, given MNKDs failures to sell Afrezza any better than SNY did. Kbrion77 is right. SNY is out of the picture and people need to let it go.
The new daily all-time lows sure make for a heck of a buying opportunity for those who still think this is going somewhere. MNKD won't get another dime from me until I see marked and significant improvement in the way they are executing their operations. The only thing that matters now is sales. Pipeline candidates and effective treatments are great but if you can't sell your products, they are worthless.
|
|
|
|
Post by mnkdfann on Nov 1, 2016 8:28:25 GMT -5
We will be in the thirties by the time a CC is held most likely. Without a R/S, the stock will need a roughly 150% increase just to make Nasdaq compliance. Think about that. I'm still waiting for an announcement of a call, if there is one at all. 3Q16 ER will be on Mon 11/14/16. Someone's crystal ball needs dusting. It is on the 9th. VALENCIA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 third quarter financial results on Wednesday, November 9, 2016 and its management will host a conference call and presentation webcast to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 9, 2016. |
|
|
|
Post by mnholdem on Nov 1, 2016 8:57:11 GMT -5
They moved up the earnings call. That could indicate that the CEO has good news and/or because they have a deadline related to an SEC filing. Man, I hope it's a signing... If it were bad news, I think the CEO would follow past practice and delay the CC to the latest possible date.  |
|
|
|
Post by peppy on Nov 1, 2016 8:58:36 GMT -5
They moved up the earnings call. That could indicate that the CEO has good news and/or because they have a deadline related to an SEC filing. Man, I hope it's a signing... the day after thanks giving, is all saints day.
www.afrezzajustbreathe.com
|
|
|
|
Post by ilovekauai on Nov 1, 2016 8:59:54 GMT -5
Let's see what unfolds. Meanwhile, I've personally been adding. I'm all in. Cheers.
|
|
|
|
Post by dictatorsaurus on Nov 1, 2016 9:01:28 GMT -5
They moved up the earnings call. That could indicate that the CEO has good news and/or because they have a deadline related to an SEC filing. Man, I hope it's a signing... Keep dreaming. |
|
|
|
Post by mnholdem on Nov 1, 2016 9:04:08 GMT -5
They moved up the earnings call. That could indicate that the CEO has good news and/or because they have a deadline related to an SEC filing. Man, I hope it's a signing... Keep dreaming. Not to be rude, but must you always piss on people's hopes? I happen to think that Epinephrine is a hot item in the market right now. |
|
|
|
Post by kbrion77 on Nov 1, 2016 9:05:31 GMT -5
3Q16 ER will be on Mon 11/14/16. . It is on the 9th. VALENCIA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 third quarter financial results on Wednesday, November 9, 2016 and its management will host a conference call and presentation webcast to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 9, 2016. Shocker. |
|
|
|
Post by dictatorsaurus on Nov 1, 2016 9:06:26 GMT -5
Not to be rude, but must you always piss on people's hopes? I happen to think that Epinephrine is a hot item in the market right now. You seem to think a lot of things. None of which has ever materialized. Theorizing moving up the earnings makes no sense. |
|
|
|
Post by mnholdem on Nov 1, 2016 9:13:16 GMT -5
Not to be rude, but must you always piss on people's hopes? I happen to think that Epinephrine is a hot item in the market right now. You seem to think a lot of things. None of which has ever materialized. Theorizing moving up the earnings makes no sense. The Wall Street Journal disagrees with you:
The Unspoken Signals in Earnings Releases
Study Finds Rescheduled Reports Hold Clues as to Direction of Profits
The idea is surprisingly simple. When companies reschedule earnings announcements, investors should look at whether the new date is earlier or later than the original date. The study suggests that companies that delay announcements are more likely to disclose earnings declines and to see their stock prices fall in the days and weeks that follow the disclosure. Conversely, companies that move up their announcements tend to announce better earnings and see their stocks rise.
Source: www.wsj.com/articles/the-unspoken-signals-in-earnings-releases-1418619058
---
...so please, go bug somebody else, preferably over at the SNY discussion board.
|
|
|
|
Post by mnkdfann on Nov 1, 2016 9:17:00 GMT -5
They moved up the earnings call. That could indicate that the CEO has good news and/or because they have a deadline related to an SEC filing. Man, I hope it's a signing... If it were bad news, I think the CEO would follow past practice and delay the CC to the latest possible date. Afaik, they ANNOUNCED the date as the 9th from the start, there was no rescheduling to speak of. Btw, if someone wanted to hide the release of bad news, the day after a hotly contested election, when the results of that will be all anyone is talking about, isn't the worst choice. Actually holding it ON election day would probably be a bit too obvious. Just kidding, but, really, not completely. (Fwiw, for weeks Yahoo Finance had pegged the estimated date as 'Earnings Date: Nov 7 - Nov 11 (Est.)'.) |
|
|
|
Post by kbrion77 on Nov 1, 2016 9:17:08 GMT -5
They moved up the earnings call. That could indicate that the CEO has good news and/or because they have a deadline related to an SEC filing. Man, I hope it's a signing... If it were bad news, I think the CEO would follow past practice and delay the CC to the latest possible date. Where did it ever say they moved up their earnings call? And please please please don't say because Lakers said the call was on the 14th. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 1, 2016 9:32:06 GMT -5
Not to be rude, but must you always piss on people's hopes? I happen to think that Epinephrine is a hot item in the market right now. I don't think you realize the impact you might have on investors. You are a sharp guy, and a moderator of this board. One might assume you know more than the average investor. You have alluded to being friends with Matt P. Now if you mix this all in with some of your claims its IMO a recipe for disaster. If you keep striking out on your predictions you have to expect people to criticize future ideas. |
|
